With over 20 years of experience in clinical operations, Tina held leadership positions at Eli Lilly and Novartis, managing operations in Taiwan and Hong Kong. Besides her corporate roles, she led Transcelerate Taiwan since 2013 and served twice as the president of the Taiwan Clinical Research Association. Tina is interested in external engagement activities through her journey in clinical operations. Her authority in the field is demonstrated further through speaker roles at universities, conferences and clinical trial training programs, particularly on GCP-related topics.
Specialties
Global clinical trials operations and management
Speaker of clinical trial topics in GCP training program, university and conference
Professional Experiences
Trial Monitoring Country Head, Novartis (Taiwan)
Head of Clinical Operations, Eli Lilly and Company (Taiwan & Hong Kong)
President of Taiwan Clinical Research Association (5th ,TCRA)
Medical representative, clinical research associate, Novartis (Taiwan)
Pharmacist, Po-Ai Hospital
Sol Han currently serves as the Chief Medical Officer (CMO) and Head of Clinical Development at Cyrus Therapeutics, a company specializing in oncology drug development. In this pivotal role, Sol is spearheading critical phases of drug development, including Investigational New Drug (IND) application submissions, early-stage clinical development, and the successful translational research that bridges non-clinical findings to human clinical trials.
With a professional background in pharmacy at Ewha Woman’s University, Sol brings two decades of deep industry experience, including 15 years garnered at Global Big Pharma companies such as Roche, GSK, and Sanofi. During this tenure, Sol established a distinguished clinical professional career as a Global Leader, successfully pioneering clinical operations and development not only locally but also globally.
Leveraging this profound expertise gained within the patient-centric and trend-setting global pharmaceutical landscape, Sol is now at Cyrus Therapeutics, successfully integrating advanced clinical development know-how into the domestic biotech sector and proactively elevating the company’s clinical capabilities to a global standard.
Sang Ho, MA is Vice President, at the Bilix which Biotech in south korea. He is expert member of MFDS (Ministry of Food & Drug Safety) & judge member of KDDF. (Korea Drug Development Fund) His current research area is acute & chronic inflammatory disease & drug delivery system. Pursuing this R&D agenda he has recently been working with global CRO & CMO. He wrote his Ph.D. on the specific chemistry for drug development at the Graduate Institute in south korea. Since 2006, he has been a senior researcher of JW Pharma & GC Pharma for more than 14 years. And he joined Bilix in 2019 and is currently the head of the research institute and Chief Development Officer.
Dr. Yun began her career at Hanmi Pharmaceuticals, took the major role in managing all activities associated with the clinical development programs for key assets including long-acting insulin, GLP-1 agonist and GLP-1/GCG dual agonist. She engaged in full courses of drug development, ranging from CDP/TPP development, clinical strategy formulation and operations, licensing out and co-development with partners. She also served as a strategic consultant in IQVIA, worked on consulting projects for key business decisions, including business planning and strategy formulation, asset valuation and pricing & reimbursement strategy for various drugs etc.
In September 2019, Dr. Yun joined to GI Innovation and has led clinical collaboration agreement of company’s immunooncology asset with global pharmaceutical companies, including MSD and AstraZeneca. She is now serving as a head of clinical development.
Dr. Yun is a registered pharmacist in Korea and was educated at School of Pharmacy, Sunkyunkwan University, where she received her PhD in pharmacology in 2012.
Ms. Juhee Jeon graduated from Korea University with a Master’s of Science in Medical Microbiology (Virology & Immunology). She has been working in the field of medical information, drug safety in clinical trial, pharmacovigilance and GCP/GVP quality management at pharmaceutical companies and CROs for more than 18 years. Currently, she is responsible for managing drug safety monitoring and pharmacovigilance at Hana Pharm in Korea.
BJ (Baek-Jae) Kim, Ph.D., is the IATA Country Manager Korea, based in Seoul, Republic of Korea. BJ leads a team of 3 (Mr. HT Lee, Ms. Anna Park, and Ms. Hyein Jeon) in the Korea field office work.
Prior to joining IATA in Aug 2019, BJ has about 25 years of aviation experience, including 6 years in United Airlines, 4 years in Air France, and 16 years in Qatar Airways as Airport Services Manager in ICN airport, the Republic of Korea.
BJ holds a Ph.D. and Master of Aviation Business Administration from the Korea Aerospace University (KAU) and a Bachelor’s degree in Economics from Hankuk University of Foreign Studies (HUFS) in the Republic of Korea.
BJ is a citizen of the Republic of Korea. He is a Christian and married with 2 children. BJ enjoys hiking, mountain climbing, and other sports in his spare time.
Since 2019 at Verimi and since early 2023 direct support of the CTO, managing different strategic topics within the Tech part of the company. Florian studied physics in Berlin, Potsdam and Princeton before gaining experience in consulting and joining the digital start-up scene in Berlin
As Head of Banking Product at Earnix, Noga is driving strategic planning and continuous development of Earnix’s Banking and Lending Product Suite, while also having hands-on involvement in implementing Earnix solutions for top lenders in the Auto lending industry. Her involvement in these implementations has provided her with valuable insights into the unique challenges and opportunities faced by financial institutions in this sector. With extensive experience as a strategic project manager in the banking industry and strategic consulting, she has led transformative initiatives in top Israeli corporations. Noga’s unique blend of customer-centric business insights and a passion for innovation fuels her drive to create groundbreaking solutions that reshape the industry’s landscape.
